Skip to content
Study details
Enrolling now

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Mohsen Saidinejad
NCT IDNCT07369024ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

120

Study length

about 2 years

Ages

5–20

Locations

1 site in CA

What this study is about

This trial is testing if a low dose of ketamine helps with pain caused by sickle cell disease. It compares the effects of ketamine plus standard pain medicine to standard pain medicine alone.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Normal Saline Placebo Infusion
  • 2.Receive Sub-dissociative Ketamine Infusion

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

anesthetic (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Drug routes

infusion

Endpoints

Secondary: ED Length of Stay, Pain Score, Quality of Life (Pediatric Quality of Life), Rate of Hospitalization